explore -WSS

explore

author：comprehensive 2025-09-29 19:57:59 - browse：1

The federal government is reforming methadone care for the first time in over two decades. But how far do the changes actually go?

To many methadone clinics, the Biden administration’s recent refresh of the rules governing opioid treatment programs represents an unprecedented opportunity to offer care that is more compassionate and responsive to patients’ needs. To many patient advocates, however, it simply nibbles around the edges.

The reality is likely somewhere in between: It will depend, in large part, on whether state-level regulators embrace the changes, and whether individual clinics actually implement them. In reform-oriented states, and at patient-centered clinics, the new rules could make a world of difference for people seeking addiction treatment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

leisure time

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

What to expect at HLTH 2023, the health care industry conference

AI can decode, harness the power of the humane immune system

CDC concerned about possible undetected monkeypox spread in U.K.

Disclosing genetic information: not as worrisome as once feared

Liquid biopsy for lung cancer is launched by Delfi

hotspot

explore

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Senate panel eyes new effort on drug shortages

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Hollywood unions extend contract negotiations for actors

Senate panel eyes new effort on drug shortages

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The science behind Janet Jackson's pregnancy at 49

Psychedelics group wrestles with new pharma identity

The strategy behind pharma's lawsuits over drug pricing reform

explore

The story of mRNA: From a loose idea to a tool that may help curb Covid

Cloning humans is technically possible. It's curious no one has tried

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Histogen: Failed biotech offers rare public look inside

3 questions for the future of Biden's cancer moonshot

The strategy behind pharma's lawsuits over drug pricing reform

hotspot

leisure time

focus

Wikipedia